

## INVITED REVIEW ARTICLE

# Improving immunological insights into the ferret model of human viral infectious disease

Julius Wong<sup>1</sup>  | Daniel Layton<sup>2</sup> | Adam K. Wheatley<sup>1</sup>  | Stephen J. Kent<sup>1,3,4</sup> 

<sup>1</sup>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Vic., Australia

<sup>2</sup>CSIRO Health and Biosecurity, Australian Animal Health Laboratories, Geelong, Vic., Australia

<sup>3</sup>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Vic., Australia

<sup>4</sup>ARC Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Vic., Australia

## Correspondence

Stephen J. Kent, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Vic., Australia.  
Email: skent@unimelb.edu.au

## Funding information

National Health and Medical Research Council, Grant/Award Number: 1129099 and 1052979

## Abstract

Ferrets are a well-established model for studying both the pathogenesis and transmission of human respiratory viruses and evaluation of antiviral vaccines. Advanced immunological studies would add substantial value to the ferret models of disease but are hindered by the low number of ferret-reactive reagents available for flow cytometry and immunohistochemistry. Nevertheless, progress has been made to understand immune responses in the ferret model with a limited set of ferret-specific reagents and assays. This review examines current immunological insights gained from the ferret model across relevant human respiratory diseases, with a focus on influenza viruses. We highlight key knowledge gaps that need to be bridged to advance the utility of ferrets for immunological studies.

## KEYWORDS

ferret, immunology, influenza

## 1 | INTRODUCTION

Animal models have proved critical in developing concepts of immunity to infection. Non-human primates (NHP) are a highly human-relevant disease model for infectious agents due to high genetic conservation between humans and NHP.<sup>1-3</sup> However, significant cost and ethical issues often necessitate the use of smaller animal models for both basic and translational research. Mice (*Mus musculus*) are a favoured small animal model due to widespread availability, incisive transgenic models, comprehensive genomic information<sup>4</sup> and readily available reagents. However, for many viruses, alternative animal models better recapitulate human physiology and disease. Ferrets (*Mustela putorius furo*) have been employed to study

the pathogenesis of a variety of human pathogens, including human and avian influenzas, coronaviruses including severe acute respiratory syndrome (SARS-CoV),<sup>5-14</sup> human respiratory syncytial virus (HRSV),<sup>15-20</sup> human metapneumovirus (HMPV),<sup>21</sup> Ebola virus<sup>22-28</sup> and henipavirus (Nipah virus and Hendra virus).<sup>29-34</sup> While ferrets can be productively infected with many of these viruses, a lack of some tools to interrogate ferret immunological responses to infection limits insights that might impact the development of vaccines and/or therapeutics. Here, we review recent insights gained from ferret models of human respiratory diseases, with a major focus on influenza, and highlight several knowledge gaps whose closure will greatly enhance the informational gain from ferret models to advance development of human vaccines and therapeutics.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. *Influenza and Other Respiratory Viruses* Published by John Wiley & Sons Ltd.

## 2 | FERRETS AS AN INFLUENZA PATHOGENESIS AND TRANSMISSION MODEL

Ferrets can be directly infected with influenza from human clinical isolates without prior adaptation. Influenza infection of ferrets recapitulates key hallmarks of human clinical disease, such as high fever accompanied by sweating, as well as respiratory symptoms such as rhinorrhea and sternutation.<sup>35,36</sup> The shared susceptibility to influenza infection is based on similarity in respiratory tract physiology, where a predominance of  $\alpha$ 2,6-linked sialic acid (SA) receptors in the upper respiratory tract of ferrets mimics that of humans,<sup>37-41</sup> unlike  $\alpha$ 2,3-SA prevalent in other species such as mice. Ferrets are an extremely valuable model for studies on influenza pathogenesis<sup>42,43</sup> and both direct and aerosol transmission.<sup>44,45</sup> Critically, ferrets are a susceptible host for highly pathogenic avian strains of influenza with pandemic potential, such as H5N1 and H7N9, although disease severity in infected ferrets is somewhat variable.<sup>42,46-48</sup> Similar variability in pathogenesis has been reported for some seasonal strains such as recent H3N2 isolates,<sup>49,50</sup> which display a range of disease severity in humans<sup>51</sup> but generally remain mild in ferrets.<sup>52,53</sup>

## 3 | FERRETS FOR INFLUENZA SURVEILLANCE AND VACCINE DEVELOPMENT

Ferrets play a critical role in annual seasonal influenza vaccine strain selection. Antigenic drift in circulating strains is monitored primarily using hemagglutination inhibition (HI) assays on serum from ferrets infected with recently circulating human viral isolates.<sup>54,55</sup> In both ferrets and humans, HI titres are a marker of protection from acquiring infection and currently the key immunological correlate for assessing potential vaccine effectiveness. Currently licensed seasonal vaccines, historically trivalent (TIV) but increasingly quadrivalent inactivated vaccines (QIV), can protect both ferrets<sup>56,57</sup> and humans<sup>58,59</sup> from infection and disease. Protection is mediated through neutralising antibodies targeting a cluster of epitopes surrounding the viral receptor-binding domain (RBD) within the highly variable hemagglutinin (HA) head domain (HA1).<sup>60,61</sup> Inactivated influenza vaccines significantly reduce mortality rates in children<sup>62,63</sup> and severe disease in adults.<sup>58,64</sup> However, vaccine protection is notoriously strain-specific, and mismatches between vaccine and circulating strains through antigenic drift lead to low vaccine efficacy.<sup>65-67</sup>

There are global efforts to increase the breadth of protection of influenza vaccines, with an eventual goal of universal protection (reviewed in<sup>68</sup>), and most strategies have been evaluated in ferret models. A non-exhaustive list of strategies to induce heterosubtypic immunity against influenza evaluated in ferrets include: HA stem vaccination<sup>69-71</sup>; prime-boost with chimeric HA-based vaccines<sup>72</sup>; use of conserved influenza proteins such as nucleoprotein (NP),<sup>73-75</sup> matrix-1 (M1),<sup>74,76</sup> matrix-2 (M2)<sup>75,77</sup> and RNA polymerase subunit

B1 (PB1)<sup>74</sup>; replication-deficient viruses<sup>78-81</sup>; live attenuated formulations<sup>82-84</sup>; the use of potent adjuvants such as Protollin,<sup>85</sup> glucopyranosyl lipid adjuvant–aqueous formulation (GLA-AF),<sup>86</sup> CoVaccine HT,<sup>87</sup> cationic adjuvant formulation<sup>88</sup> and poly-g-glutamic/chitosan nanogel<sup>89</sup>; *Escherichia coli*-derived vaccines<sup>90</sup>; DNA, mRNA and viral vector vaccines<sup>75,91-93</sup>; and the use of virus-like particles (VLP).<sup>76</sup> Additional examples of important ferret studies include (but are not limited to) evaluating the influence of changing the route of influenza inoculation on subsequent immunity<sup>94</sup> and the use of neuraminidase (NA) inhibitors as prophylaxis.<sup>95</sup>

## 4 | FERRETS AS AN IMMUNOLOGICAL MODEL FOR STUDYING INFLUENZA

The utility of ferrets for incisive immunological studies is hampered by limited reagents to study ferret immunity and a paucity of background knowledge about the ferret immune system. Some insights into ferrets' immunological responses to influenza have been gained by indirect measurements of immune gene expression such as quantitative RT-PCR (qRT-PCR), transcriptome analysis or oligonucleotide microarrays.<sup>22,96-100</sup> For example, assessing the differential expression levels of innate and adaptive immune genes in the lungs following primary or secondary 2009 H1N1pdm infection revealed upregulation of interferon-stimulated genes involved in antiviral responses such as C-X-C motif chemokine 10 (CXCL10), 2'-5' oligoadenylate synthase 1 (OAS1), interferon regulatory factor 1 (IRF1) and radical S-adenosyl methionine domain containing 2 (RSAD2) as well as chemokines such as CXCL16 and C-C motif chemokines 3, 4 and 5 (CCL3, CCL4 and CCL5).<sup>98</sup> Similarly, the degree of disease severity, virus shedding and transmission in ferrets has been associated with tumour necrosis factor (TNF) and interleukin-6 (IL-6) mRNA expression in the upper respiratory tract.<sup>97</sup> However, mRNA levels can correlate poorly with protein levels,<sup>101</sup> and techniques such as flow cytometry, bead arrays and immunohistochemistry would facilitate direct measurement of immune marker expression. To date, flow cytometric or microscopy techniques have been limited in ferrets by the lack of suitable antibodies specific for ferret immune cell markers.

Screening for cross-species reactivity has identified antibody clones recognising ferret T-cell markers such as CD3 and CD8, and an intracellular B-cell marker CD79b<sup>102-104</sup> (summarised in Table 1). The utility of such cross-reactive reagents has been shown experimentally. For example, prime-boost immunisation using DNA and adenoviral-based influenza vaccines provided effective protection in experimentally challenged ferrets, with protection correlating to the capacity of CD3+ T cells to express interferon gamma (IFN- $\gamma$ ) following in vitro stimulation on peripheral blood mononuclear cells (PBMCs) with HA peptide pools.<sup>92</sup> Caution should be taken when using antibodies developed for other species in ferret experiments, as there may be subsets of cells displaying variable reactivity to the antibodies.<sup>105,106</sup> In addition, currently available anti-ferret B-cell antibodies such as CD79 $\alpha$  target intracellular epitopes, requiring

**TABLE 1** List of currently available reagents available for studying ferret immune cells

Antigen	Species	Clonality-Clone	Cell type	Reference(s)
CD20	Human	Polyclonal—RB-9013-P	B	108,163
CD32	Human	Monoclonal—2E1	B	102
CD79a	Human	Monoclonal—HM47/HM57	B	108,163
CD79b	Human	Monoclonal—ZL9-2	B	102
IgA	Ferret	Polyclonal—NBP-72747	B	124
IgA	Canine	Polyclonal	B	102
IgA/G/M	Ferret	Polyclonal	B	108
IgG	Ferret	Polyclonal	B	commercially available
IgG	Mink	Polyclonal	B	102,175
IgM	Ferret	Polyclonal	B	commercially available
IgM	Human	Polyclonal	B	102
Kappa	Ferret	Monoclonal—multiple	B	118
Lambda	Ferret	Monoclonal—multiple	B	118
Immunoglobulin Heavy chain	Ferret	Monoclonal—multiple	B	118
CD11b	Mouse	Monoclonal—M1/70	Innate	103,108
CD14	Human	Monoclonal—Tuk40	Innate	102
CD172a	Human	Monoclonal—DH59B	Innate	102
CD163	Swine	Monoclonal—2A10/11	Innate	163
MAC387	Human	Monoclonal—M0747	Innate	163
CD88	Human	Monoclonal—S5/1	Innate	102
SWC3	Swine	Monoclonal—BA1C11	Innate	163
CD43	Mouse	Monoclonal—S7	Pan-leucocyte	103
LFA-1	Mouse	Monoclonal—2D7	Pan-leucocyte	103
Ly6C	Mouse	Monoclonal—AL-21	Pan-leucocyte	108
TNF	Mouse	Monoclonal—MP6-XT22	Pan-leucocyte	103
MHC-II	Human	L243	T	108
CD3	Human	Polyclonal—IS503	T	163
CD103	Mouse	Monoclonal—M290	T	103
HLA-DR	Human	Monoclonal—TAL.1B5	T	163
CD25	Human	Monoclonal—B1.49.9	T	102
CD4	Ferret	CL3.1.5	T	108
CD4	Ferret	Monoclonal	T	107
CD8	Human	Monoclonal—OKT8	T	102,103,108
CD8	Ferret	Polyclonal—60001RPO2	T/NK	163
IL-4	Bovine	Monoclonal—CC303	T	103
Thy1.1	Mouse	Monoclonal—OX-7	T	103
IFN- $\gamma$	Bovine	Monoclonal—CC302; XMG1.2	T/NK	103

fixation and permeabilisation. This limits downstream applications such as RT-PCR or the recovery of antigen-specific immunoglobulin sequences from sorted B cells. In the absence of cross-reactive

clones, several groups have generated novel monoclonal antibodies specific for ferret cellular markers. For example, novel anti-ferret CD4-, CD8- and CD5-specific antibodies were derived by

immunising mice with the CD4 ectodomain,<sup>107</sup> whole CD4 protein<sup>108</sup> or ferret thymocytes.<sup>83</sup> Efforts to develop novel antibody-based reagents to define various ferret immune cell subpopulations are accelerating, particularly through the Centers of Excellence for Influenza Research and Surveillance (CEIRS) network,<sup>109</sup> and are reviewed in detail further below.

Using existing reagents, innate and adaptive immune responses to influenza infection<sup>52,108,110</sup> and immunisation<sup>83,111</sup> have been studied and provide important insights into ferret antiviral immunity. Following influenza challenge of naïve or vaccinated ferrets, there is a transient increase in CD11b<sup>+</sup> expressing PBMCs at 2 d.p.i, which decreased to baseline levels by 3 d.p.i, suggesting a role for monocytes/macrophages/neutrophils or antigen-presenting cells (APC) during early infection.<sup>110,111</sup> In addition, an infiltration of CD11b<sup>+</sup> and MHC-II<sup>+</sup> cells into lungs between 2 and 5 d.p.i was observed, which could represent lung APCs.<sup>110</sup> CD11b<sup>+</sup> cells also increase in secondary lymphoid organs 10 d.p.i,<sup>108</sup> suggesting a coordinated immune response involving both innate and adaptive responses to resolve infection.

Ferrets have also been employed to examine the spatiotemporal dynamics of B- and T-cell responses after vaccination or infection with different influenza strains.<sup>52,110</sup> Immunologically naïve or primed ferrets challenged<sup>110,111</sup> with influenza A virus (IAV) are observed to have transient blood CD4<sup>+</sup> T/CD8<sup>+</sup> T-cell lymphopenia.<sup>110</sup> Correspondingly, influenza-specific serum IFN- $\gamma$  responses increased by 5-7 d.p.i which remain elevated up to 14-34 d.p.i.<sup>52,83</sup> This is consistent with the increase in CD8<sup>+</sup> frequencies by 10-34 d.p.i in vaccinated/infected ferrets<sup>83,108</sup> and influenza-reactive CD4<sup>+</sup> cells by 8-34 d.p.i in draining lymph nodes.<sup>52,83</sup> Further comparison of IFN- $\gamma$ -expressing T-cell responses during an infection in lung and blood PBMCs suggested H1 and H3 establish infection in different organ compartments, since IFN- $\gamma$ -expressing T-cell responses in the lungs of H3-infected ferrets were significantly lower than H1-infected ferrets.<sup>52</sup> This is consistent with other studies showing limited replication of H3 viruses in ferret lungs.<sup>111-113</sup>

The influenza protein specificity of the T-cell response to influenza is beginning to be explored in ferrets using IFN- $\gamma$  expression assays and other standardised protocols.<sup>108,114</sup> DiPiazza et al<sup>108</sup> found that the majority of bulk memory CD4<sup>+</sup> T-cell responses were specific for the M1 protein whereas non-structural protein (NS) was mainly the target for CD8<sup>+</sup> T-cell responses, and hierarchical responses were found to change over time without preferential retention of immunodominant specificities.<sup>115</sup> In comparison, cross-reactive ferret CD4<sup>+</sup> T cells recognise HA and NA epitopes preferentially whereas CD8<sup>+</sup> T cells mount immune responses towards M1, NS2 and RNA polymerase subunit A (PA), with NP as a significant antigenic target.<sup>104</sup> Interrogation of ferret T-cell responses with improved reagents will increase our understanding of immunodominance hierarchies analogous to studies performed in other animal models and humans (reviewed in<sup>116</sup>).

Markers targeting B-cell antigens such as CD79a, CD20 and surface immunoglobulin also allow ferret B cells to be examined by immunohistochemistry and flow cytometry in ferret tissues.<sup>108,117,118</sup>

B-cell frequencies are also transiently decreased 2 d.p.i.<sup>110,111</sup> after infection, with a corresponding increase in secondary lymphoid organs 2-5 d.p.i.<sup>110</sup> The number of major histocompatibility complex (MHC-II) expressing cells also increased, with no significant difference in surface immunoglobulin-positive cells by 10 d.p.i.<sup>108</sup> Influenza-specific ASCs were also increased by 37 d.p.i, highlighting the role of B cells in the resolution of infection.<sup>83</sup> These observations suggest changes in the maturation status of B cells after activation and mirror observations in humans and mice (as reviewed in<sup>119</sup>). MHC-II is upregulated in B cells to induce germinal centre formation (GC) through cognate interactions with T follicular helper cells (T<sub>FH</sub>). This has been demonstrated in mice, where the ablation of MHC-II expression in mice led to a decrease in influenza-specific IgG and IgA titres and decreased survival rates.<sup>120</sup> Surface immunoglobulin expression in antibody-secreting plasma cells (ASCs) is also downregulated, consistent with the decrease in the number of surface immunoglobulin expressing HA-reactive GC cells by 14 d.p.i.<sup>121</sup>

Similar to T cells, B-cell HA immunodominance hierarchies have been studied widely.<sup>122</sup> A key target for broader antibody responses is the conserved stem domain (HA2) of HA; however, immunodominant responses against HA1 often limit antibody responses to variable regions, leading to escape from host responses.<sup>123</sup> Different vaccination strategies to induce broadly protective antibody responses have been studied in ferrets.<sup>124</sup> Using purified ferret immunoglobulins and cross-reactive polyclonal immunoglobulin antisera from mink, goat, canine and rabbits, a ferret immunoglobulin class-specific ELISA was developed.<sup>102</sup> By exposing ferrets to recombinant HA constructs with exotic HA head domains via infections and vaccinations (H9/H8/H5 head domain with H1 stem domain), immunologically subdominant anti-HA stem responses were induced as measured by ELISA.<sup>124</sup> Polyclonal stem-reactive antibodies were detected serologically and protected ferrets against pH1N1 challenge in the presence of low neutralisation activities as measured by microneutralisation assays. This is consistent with studies in other mammalian models and humans suggesting that Fc-mediated functions are important for HA2-mediated protection (as reviewed in<sup>125</sup>). Further delineation of such immunodominance hierarchies in HA at the monoclonal antibody level and functional characterisation of HA2-specific antibodies are reviewed in detail further below.

The effects of prior infection on host susceptibility to re-infection, that is viral interference, have also been studied in ferrets.<sup>126</sup> Ferrets sequentially challenged with B/Victoria and B/Yamagata viruses display decreased virus shedding, which correlated with the induction of high frequencies of cross-reactive IFN- $\gamma$ -expressing T-cell responses between initial infection and heterologous challenge.<sup>127</sup> Infection with A(H1N1)pdm09 was also shown to prevent HRSV infections in ferrets, though no IFN- $\gamma$  responses or cross-reactive serological responses were observed, suggesting different underlying mechanisms driving viral interference between unrelated viruses.<sup>128</sup> This observation mirrors epidemiological studies in humans, where peak incidences

of HRSV infections in humans were delayed by influenza A outbreaks (reviewed in<sup>128</sup>).

Several key questions remain unanswered in ferrets with regard to influenza-specific immune responses. First, chemotactic signals important for the spatiotemporal distribution of immune cells are still largely unknown in ferrets; for example, influenza-infected epithelial cells secrete CCL-2 which recruits monocytes to the lungs during early infection and may be associated with acute lung injury<sup>129</sup> during severe infections. Secondly, different innate immune subsets such as natural killer (NK) cells, dendritic cells (DCs), monocyte/macrophages and granulocytes have also yet to be studied in detail, and development of reagents to allow the delineation of these cell populations (reviewed in<sup>130-133</sup>) will enable a more detailed picture of early immune responses in ferrets. Thirdly, while adaptive immune responses have been studied in ferrets, markers to delineate B/T-cell subpopulations will be useful to study long-term protection against influenza infection (as reviewed in<sup>134</sup>). Examples include CD62L and CD44 for naïve and memory T cells, and IgD and CD27 for naïve and memory B cells, respectively.

## 5 | FERRETS AS AN IMMUNOLOGICAL MODEL FOR OTHER EMERGING VIRAL DISEASES

In addition to influenza, the ferret serves as a critical model for other important human pathogens such as SARS-CoV, pneumoviruses (HRSV and HMPV), Ebola virus and henipaviruses. While these infections remain less characterised in comparison with influenza, the ferret provides a platform to examine disease pathogenesis and transmission and to evaluate potential vaccine efficacy. However, like influenza, evaluation of host immune responses in ferrets is commonly restricted to gene expression analyses.

### 5.1 | SARS-CoV

SARS-CoV infection causes acute respiratory distress in humans with mortality rates of up to 10%.<sup>135</sup> While worldwide outbreaks have not been reported since 2004, there is still a lack of vaccines and effective treatment measures. Ferrets display clinical signs of infection such as elevated body temperatures, sneezing, increase in lymphocyte counts and lesions in the respiratory tract and alveolar oedema<sup>7</sup> and are therefore a good mammalian model to study the pathogenesis of SARS-CoV (reviewed in<sup>7,136</sup>) and evaluate vaccines (reviewed in<sup>14,137-139</sup>). In terms of immunity, ferrets exhibit strong antiviral interferon responses after infection and vaccination as measured by interferon response gene expression levels.<sup>5,13</sup> However, leucocyte counts and interferon-related gene expression were decreased upon re-infection,<sup>5</sup> suggesting that innate immune dysregulation is a possible mechanism of pathogenesis, though a protective antibody response was also evident during attempts to re-infect ferrets.<sup>8</sup>

### 5.2 | Henipavirus

Emerging viruses belonging to the *Paramyxoviridae* family (Henipaviruses) can cause severe respiratory illness and/or encephalitis in humans. Ferrets infected with henipaviruses exhibit similar symptoms as humans including respiratory signs such as cough and nasal discharge, neural signs such as depression,<sup>32</sup> and high mortality rates with most experimentally infected ferrets succumbing within 1 week.<sup>31</sup> While the virus is detected in pharyngeal and rectal secretions, it is currently unclear if ferrets could serve as a transmission model for the disease.<sup>31,32</sup> Ferrets infected intranasally with henipaviruses similarly display clinical illness.<sup>31,34</sup> Assessment of immune gene expression by Leon et al<sup>31</sup> in both lungs and brain tissues of the infected ferrets revealed upregulation of macrophage markers such as CD40 and CD80 in both lung and brain tissues, whereas lymphocytic markers were unchanged in the lungs.

### 5.3 | Respiratory syncytial virus and metapneumovirus

RSV and HMPV cause severe respiratory disease in young children, the elderly and immunocompromised patients. Both RSV and HMPV readily infect ferrets but in general do not exhibit signs of disease.<sup>15,20,21</sup> Nevertheless, ferrets have proven to be a useful model to study RSV. Several groups have successfully infected ferrets with a wild-type strain of human RSV and demonstrated efficient replication in both the upper and lower respiratory tracts of adult ferrets,<sup>15,20</sup> consistent with humans where infection is often limited to the upper respiratory tract.<sup>140</sup> Immunocompromised ferrets, induced by oral administration of immunosuppressive drug mycophenolate mofetil (MMF), demonstrate prolonged RSV shedding and effective contact transmission to both immunocompetent and immunocompromised ferrets,<sup>18</sup> confirming antiviral immunity in the ferret can curtail viral replication. An assessment of lung immune gene expression in ferrets infected with RSV demonstrated an upregulation of proinflammatory cytokines such as interleukin-1 alpha (IL-1 $\alpha$ ) and interleukin-1 beta (IL-1 $\beta$ ) by 5 d.p.i which coincided with maximum levels of RSV mRNA, while levels of other cytokines such as interferon alpha (IFN- $\alpha$ ) and IFN- $\gamma$  remained unchanged.<sup>20</sup> In terms of humoral responses, increased serum titres of fusion (F) glycoprotein antibodies were seen by 15 d.p.i<sup>20</sup> that were protective against re-infection.

### 5.4 | Ebola virus

Ebola virus disease (EVD) is caused by a zoonotic virus from the *Filoviridae* family of viruses.<sup>28</sup> This disease can transmit from human to human and causes acute and often fatal disease. Ferrets are able to be directly infected with the Zaire, Bundibugyo and Sudan Ebola strains,<sup>22,23</sup> which have previously caused major human outbreaks. Ferrets display hallmarks of pathological processes of human lethal infections such as petechial rashes, reticulated pallor of the liver and

splenomegaly.<sup>23,24</sup> Transmission has also been reported in ferrets.<sup>141</sup> As for immunological studies, transcriptomic sequencing in ferrets infected with lethal doses (1000 plaque-forming units (PFU)) of the Makona variant of *Zaire ebolavirus* revealed upregulation of proinflammatory-related genes such as interferon activation, Toll-like receptor signalling, interleukin-1/6 responses and coagulation cascades by 5 d.p.i.<sup>142</sup>

## 6 | KEY KNOWLEDGE GAPS TO ADDRESS IN ORDER TO IMPROVE THE IMMUNOLOGICAL UTILITY OF FERRET MODELS

While the ferret model has unique potential for informative studies into pathogenic viral infections as noted above, addressing several key knowledge gaps will substantially advance the ferret as an immunological model.

### 6.1 | Immunogenetics

There is a lack of well-annotated, ferret genomic sequence information to characterise immune responses, limiting the scope of molecular analyses that can be performed; ferret T/B-cell receptor repertoire analysis is currently not possible. Next-generation sequencing (NGS) has become increasingly important for immunological research and has led to the generation of huge amounts of data and the development of tools for data extraction and analysis. An important aspect of T- and B-cell research is the immune cell receptor repertoire during an infection and the effects of allelic variation of important immunological molecules such as major histocompatibility complex (MHC) on host immune responses. A draft copy of the ferret genome is available,<sup>62</sup> but genes coding for B- or T-cell receptors have yet to be fully annotated and validated. Genomic sequencing and assembly of closely related species such as minks<sup>143</sup> are also far from complete, though several similarities such as genome size and relative abundance of repeat elements have been found. In comparison, high-quality draft genome assemblies for dogs and cats are available and have been used for genome-wide association studies<sup>144</sup> and identification of single nucleotide polymorphisms (SNPs).<sup>145</sup> The identification of SNPs in immunoglobulin genes is useful for distinguishing between somatically mutated B-cell receptor sequences and germline variants in affinity-matured antigen-specific B-cell populations. There are currently databases of immunoglobulin sequences for well-established animal models such as those found in the international ImMunoGeneTics (IMGT) information system database<sup>146</sup> and have been useful for identifying somatic hypermutations in immunoglobulin sequences.<sup>147</sup> A curated and annotated database of immune gene sequences is a prerequisite for PCR primer design and post-sequencing data analysis used to recover and express antibodies from single-sorted B cells<sup>148</sup> and recombinant T-cell receptors.<sup>149</sup>

### 6.2 | Future T cell-specific reagents for ferrets

Future development of markers to delineate more T-cell subsets will increase the utility of the ferret as an immunological model; a recent report listed several important ferret T cell-specific antibodies to be in production at the CEIRS such as CD4, CCR7, CD3e, CD40, CD40L, CD44, CD62L, CD69, CD103, PD-1, CXCR3, CXCR5, IL-7R and IL-15R.<sup>109</sup>

### 6.3 | Future B cell-specific reagents for ferrets

To increase our understanding of antibody responses in ferrets, flow cytometric reagents that are able to delineate B-cell subsets are required. Important ferret B cell-specific antibodies that are in production at the CEIRS include CD83, CD86, CD95, CD19, CD20, CD25, CD27, CD38, CD138 and FcR.<sup>109</sup>

### 6.4 | Current and future markers for ferret myeloid lineage cells

Several markers defining innate cell populations in mice and humans such as CD11b<sup>103,108</sup> and CD14<sup>102</sup> have also been reported to cross-react with ferret leucocytes and have been utilised to characterise ferret innate immune responses. However, these markers have also been found to be expressed in non-myeloid lineages in humans,<sup>150,151</sup> and other markers such as CD16<sup>152</sup> and CD66<sup>153</sup> will be required to better define myeloid cell populations.

### 6.5 | Ferret immunoglobulin subclass and Fc receptors

Ferret immunoglobulin subclass and Fc receptors are not well studied. Currently, only one IgG subclass that has been identified in ferrets, while four different IgG subclasses have been identified in other carnivores such as dogs<sup>154</sup> and minks<sup>155</sup> and three in felines,<sup>156</sup> suggesting other unidentified ferret IgG subclasses may exist. The diversity and function of ferret Fc receptors are also unknown. Different IgG and Fc receptor subclasses in humans and mice have shown to be important for different antibody-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC). Human Fc gamma receptor IIIa (FcγRIIIa; FcγRIV in mice) is the main receptor involved in ADCC, and human IgG3 (mouse IgG2a) followed closely by human IgG1 (mouse IgG2b) displays the highest affinities for this receptor. Advanced assays for ADCC and other Fc-mediated responses to influenza have been developed in recent years in both NHP<sup>157</sup> and humans.<sup>158,159</sup> Such non-neutralising mechanisms have been shown to be important for broadly protective responses against antigenically distinct strains of influenza<sup>157,160,161</sup> and development of universal influenza vaccines. Many of the current ADCC and related assays rely on the detection of Ab-mediated activation of NK cells to express cytokines such as IFN-γ or degranulation markers such as CD107a,<sup>162</sup> but there are currently no reagents to differentiate NK cells from other cytotoxic lymphocyte populations

such as CD8+ T cells.<sup>163</sup> While a ferret-specific T-cell IFN- $\gamma$  expression assays<sup>164</sup> to measure CD8 T-lymphocyte activation have been developed and validated, the future elucidation of corresponding antibody/Fc receptor ferret orthologues will enable ferrets to be used to evaluate ADCC responses.

## 6.6 | Antigenic recognition of major influenza proteins

Epitope mapping studies using either human or murine monoclonal antibodies have greatly increased our understanding of influenza viral evolution and allowed the identification of major HA epitopes and pathways of immune escape. While factors that determine the dominant escape mutants are still unknown, such studies have the potential to improve the process of influenza vaccine design. The inability to isolate monoclonal antibodies from ferret B cells has limited studies into the antigenic recognition of influenza proteins in ferrets. Confirming epitope-specific recognition of HA at the monoclonal antibody level in ferrets is critical, as there have been several reports that human and ferret serum antibodies can display variable antigenic recognition.<sup>165,166</sup> This is critically important as antisera from infected ferrets is widely used in HI assays as part of the strain determination process for influenza vaccines.<sup>167,168</sup>

Major antigenic sites of HA have been localised by generating viral escape mutants in the presence of influenza-specific murine<sup>169,170</sup> or human<sup>171</sup> monoclonal antibodies, which for H1N1 viruses have been termed Sa, Sb, Ca1, Ca2 and Cb.<sup>170</sup> A study of influenza A (IAV) HA antigenic sites using engineered viruses with mutations in each of the antigenic sites surrounding the RBD revealed species-specific differences in antibody recognition.<sup>166</sup> HI activities against H1N1 (A/Michigan/45/2015) mutants as described revealed differences in antigenic epitopes recognised by mice, guinea pigs, ferrets and adult humans using serum samples. For example, neutralising antibodies in adult humans recognised mostly Sb and Sa, while responses in ferrets were mostly directed to Sa.<sup>166</sup> Another similar study characterising humoral responses against influenza B (IBV) using reverse-engineered viral mutants showed that the proportion of human antibodies targeting non-canonical antigenic sites of IBV HA are comparable to canonical antigenic sites (120 loop, 150 loop, 160 loop and 190 helix).<sup>172</sup> This is in contrast to IBV-specific responses in mice and ferrets, where most serum antibody is directed against canonical antigenic sites only. These results suggest inter-species differences in humoral recognition of the influenza HA. Other studies lend support, with a head-to-head comparison between humans and ferrets immunised or infected with various seasonal H3 vaccine strains showing key differences in serological recognition of viral HA<sup>173</sup> based on molecular modelling and antigenic cartography. Similarly, cross-reactive H1N1 antibody responses in ferrets are not predictive of cross-reactive responses in humans,<sup>174</sup> confirming fundamental differences in B-cell responses between humans and ferrets.

## 7 | CONCLUSION

Ferrets have tremendous utility for studying the pathogenesis and transmission of several human respiratory diseases and for pre-clinical evaluation of vaccines. Ferrets are a critically important model that directly impacts human seasonal influenza vaccine selection and the pre-clinical development of vaccines for other emerging diseases. However, knowledge gaps limit the in-depth assessment of any immune mechanisms that may underpin transmission, protection and/immunopathology of these viral diseases in the ferret model. There is an urgent need for novel reagents with well-validated and specific targets to resolve different immune cell populations. Improving the ferret model to enable the application of insightful modern immunological tools, such as single-cell B-cell receptor sequencing, next-generation sequencing platforms and other bioinformatics tools, will greatly enhance the informative value of the ferret model which will in turn lead to better immunological interventions for human respiratory diseases.

## ACKNOWLEDGEMENTS

This work was supported by NHMRC programme grant #1052979 (SJK) and NHMRC project grant #1129099 (AKW). JW is supported by a Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship.

## CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## AUTHOR CONTRIBUTIONS

JW performed literature review and prepared the manuscript. DL, SK and AW edited and provided comments. All authors contributed to the formulation of this scientific research topic.

## ORCID

Julius Wong  <https://orcid.org/0000-0003-0253-6151>

Adam K. Wheatley  <https://orcid.org/0000-0002-5593-9387>

Stephen J. Kent  <https://orcid.org/0000-0002-8539-4891>

## REFERENCES

1. Rogers J, Gibbs RA. Comparative primate genomics: emerging patterns of genome content and dynamics. *Nat Rev Genet.* 2014;15(5):347-359.
2. Przeworski M, Enard D, Depaulis F, Roest Crolius H. Human and non-human primate genomes share hotspots of positive selection. *PLoS Genet.* 2010;6(2):e1000840.

3. Osada N. Genetic diversity in humans and non-human primates and its evolutionary consequences. *Genes & Genetic Syst.* 2015;90(3):133-145.
4. Guenet JL. The mouse genome. *Genome Res.* 2005;15(12):1729-1740.
5. Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. *PLoS ONE.* 2012;7(9):e45842.
6. Thiel V, Cameron MJ, Kelvin AA, et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret. *Model. PLoS ONE.* 2012;7(9):e45842.
7. van den Brand JM, Haagmans BL, van Riel D, Osterhaus AD, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. *J Comp Pathol.* 2014;151(1):83-112.
8. Chu YK, Ali GD, Jia F, et al. The SARS-CoV ferret model in an infection-challenge study. *Virology.* 2008;374(1):151-163.
9. van den Brand J, Haagmans BL, Leijten L, et al. Pathology of experimental SARS coronavirus infection in cats and ferrets. *Vet Pathol.* 2008;45(4):551-562.
10. Hu Y, Li W, Gao T, et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. *J Virol.* 2017;91(8):e02143-16.
11. Hu W, Yen YT, Singh S, Kao CL, Wu-Hsieh BA. SARS-CoV regulates immune function-related gene expression in human monocytic cells. *Viral Immunol.* 2012;25(4):277-288.
12. Darnell Miriam ER, Plant Ewan P, Watanabe H, et al. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. *J Infect Dis.* 2007;196(9):1329-1338.
13. Danesh A, Cameron CM, León AJ, et al. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. *Virology.* 2011;409(1):102-112.
14. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. *Vaccine.* 2005;23(17-18):2273-2279.
15. Stittelaar KJ, de Waal L, van Amerongen G, et al. Ferrets as a novel animal model for studying human respiratory syncytial virus infections in immunocompetent and immunocompromised hosts. *Viruses.* 2016;8(6):168.
16. Taylor G. Animal models of respiratory syncytial virus infection. *Vaccine.* 2017;35(3):469-480.
17. Prince GA, Porter DD. The pathogenesis of respiratory syncytial virus infection in infant ferrets. *Am J Pathol.* 1976;82(2):339-352.
18. de Waal L, Smits SL, Veldhuis Kroeze E, et al. Transmission of human respiratory syncytial virus in the immunocompromised ferret. *Model. Viruses.* 2018;10(1):18.
19. Coates HV, Chanock RM. Experimental infection with respiratory syncytial virus in several species of animals. *Am J Hyg.* 1962;76:302-312.
20. Chan KF, Carolan LA, Druce J, et al. Pathogenesis, humoral immune responses and transmission between co-housed animals in a ferret model of human RSV infection. *J Virol.* 2017;92(4):e01322-17.
21. MacPhail M, Schickli JH, Tang RS, et al. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. *J Gen Virol.* 2004;85(Pt 6):1655-1663.
22. Carolan LA, Rockman S, Borg K, et al. Characterization of the localized immune response in the respiratory tract of ferrets following infection with influenza A and B viruses. *J Virol.* 2015;90(6):2838-2848.
23. Kozak R, He S, Kroeker A, et al. Ferrets infected with Bundibugyo virus or Ebola virus recapitulate important aspects of human filovirus disease. *J Virol.* 2016;90(20):9209-9223.
24. Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW. The domestic ferret (*Mustela putorius furo*) as a lethal infection model for 3 species of Ebolavirus. *J Infect Dis.* 2016;214(4):565-569.
25. Wec AZ, Herbert AS, Murin CD, et al. Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses. *Cell.* 2017;169(5): 878-890.e15.
26. Nesspor TC, Scallan B. Chimeric antibodies with extended half-life in ferrets. *Influenza Other Respir Viruses.* 2014;8(5):596-604.
27. Hassanin A, Nesi N, Marin J, et al. Comparative phylogeography of African fruit bats (Chiroptera, Pteropodidae) provide new insights into the outbreak of Ebola virus disease in West Africa, 2014-2016. *C R Biol.* 2016;339(11-12):517-528.
28. Bukreyev AA, Chandran K, Dolnik O, et al. Discussions and decisions of the 2012-2014 international committee on taxonomy of viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. *Arch Virol.* 2014;159(4):821-830.
29. Balzer M. Hendra vaccine success announced. *Aust Vet J.* 2011;89(7):N2-3.
30. Pallister J, Middleton D, Wang L-F, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. *Vaccine.* 2011;29(34):5623-5630.
31. Leon AJ, Borisevich V, Boroumand N, et al. Host gene expression profiles in ferrets infected with genetically distinct henipavirus strains. *PLoS Negl Trop Dis.* 2018;12(3):e0006343.
32. Geisbert TW, Feldmann H, Broder CC. Animal challenge models of henipavirus infection and pathogenesis. *Henipavirus.* 2012;153-177.
33. Berhane Y, Weingartl HM, Lopez J, et al. Bacterial infections in pigs experimentally infected with Nipah virus. *Transbound Emerg Dis.* 2008;55(3-4):165-174.
34. Pallister JA, Klein R, Arkinstall R, et al. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. *Viol J.* 2013;10:237.
35. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am J Epidemiol.* 2008;167(7):775-785.
36. Beigel JH. Influenza. *Crit Care Med.* 2008;36(9):2660-2666.
37. Ng PS, Bohm R, Hartley-Tassell LE, et al. Ferrets exclusively synthesize Neu5Ac and express naturally humanized influenza A virus receptors. *Nat Commun.* 2014;5:5750.
38. Johnson-Delaney CA, Orosz SE. Ferret respiratory system: clinical anatomy, physiology, and disease. *Vet Clin North Am Exot Anim Pract.* 2011;14(2):357-367.
39. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. *Nature.* 2006;440(7083):435-436.
40. van Riel D, Munster VJ, de Wit E, et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. *Am J Pathol.* 2007;171(4):1215-1223.
41. Hemmink JD, Whittaker CJ, Shelton HA. Animal models in influenza research. *Influenza Virus.* 2018;401-430.
42. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. *J Virol.* 2002;76(9):4420-4429.
43. Belser JA, Eckert AM, Tumpey TM, Maines TR. Complexities in ferret influenza virus pathogenesis and transmission models. *Microbiol Mol Biol Rev.* 2016;80(3):733-744.
44. Buhnerkempe MG, Gostic K, Park M, Ahsan P, Belser JA, Lloyd-Smith JO. Mapping influenza transmission in the ferret model to transmission in humans. *Elife.* 2015;4:e07969.
45. Frise R, Bradley K, van Doremalen N, et al. Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. *Sci Rep.* 2016;6:29793.



46. van den Brand Judith MA, Stittelaar Koert J, van Amerongen G, et al. Severity of pneumonia due to New H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. *J Infect Dis*. 2010;201(7):993-999.
47. Moore IN, Lamirande EW, Paskel M, Donahue D, Qin J, Subbarao K. Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. *J Virol*. 2014;88(23):13879-13891.
48. Belshaw R, Paulo AC, Correia-Neves M, Domingos T, Murta AG, Pedrosa J. Influenza infectious dose may explain the high mortality of the second and third wave of 1918-1919 influenza pandemic. *PLoS ONE*. 2010;5(7):1918-1919.
49. Allen JD, Ross TM. H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. *Hum Vaccin Immunother*. 2018;14(8):1840-1847.
50. Lefevre C, Behillil S, Triau S, et al. Fatal myopericarditis following an influenza A (H3N2) infection. *Am J Case Rep*. 2018;19:540-544.
51. Figueredo AL, Minchole E, Panadero C, et al. Clinical and epidemiological features in H1N1 and H3N2 influenza A virus. *10.1 Respiratory Infections*. 2015.
52. Ryan KA, Slack GS, Marriott AC, et al. Cellular immune response to human influenza virus differs between H1N1 and H3N2 subtypes in the ferret lung. *PLoS ONE*. 2018;13(9):e0202675.
53. Moore IN, Lamirande EW, Paskel M, et al. Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. *J Virol*. 2014;88(23):13879-13891.
54. Hensley SE, Harvey WT, Benton DJ, et al. Identification of low- and high-impact hemagglutinin amino acid substitutions that drive antigenic drift of influenza A(H1N1) viruses. *PLoS Pathog*. 2016;12(4):e1005526.
55. Sandbulte MR, Westgeest KB, Gao J, et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. *Proc Natl Acad Sci USA*. 2011;108(51):20748-20753.
56. Pearce MB, Belser JA, Gustin KM, et al. Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets. *J Virol*. 2012;86(13):7118-7125.
57. Sambhara S, Skowronski DM, Hamelin M-E, et al. Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease. *Risk. PLoS ONE*. 2014;9(1):e86555.
58. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev*. 2010;2:CD004876.
59. Arriola CS, Anderson EJ, Baumbach J, et al. Does influenza vaccination modify influenza severity? Data on older adults hospitalized with influenza during the 2012-2013 season in the United States. *J Infect Dis*. 2015;212(8):1200-1208.
60. Matsuzaki Y, Sugawara K, Nakauchi M, et al. Epitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants. *J Virol*. 2014;88(21):12364-12373.
61. Guo Z, Wilson JR, York IA, Stevens J. Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus. *J Immunol Methods*. 2018;461:23-29.
62. Flannery B, Reynolds SB, Blanton L, et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. *Pediatrics*. 2017;139(5):2010-2014.
63. Blyth CC, Jacoby P, Effler PV, et al. Influenza vaccine effectiveness and uptake in children at risk of severe disease. *Pediatr Infect Dis J*. 2016;35(3):309-315.
64. Arriola C, Garg S, Anderson EJ, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clin Infect Dis*. 2017;65(8):1289-1297.
65. Alfelali M, Khandaker G, Booy R, Rashid H. Mismatching between circulating strains and vaccine strains of influenza: effect on Hajj pilgrims from both hemispheres. *Hum Vaccin Immunother*. 2016;12(3):709-715.
66. Sah P, Medlock J, Fitzpatrick MC, Singer BH, Galvani AP. Optimizing the impact of low-efficacy influenza vaccines. *Proc Natl Acad Sci USA*. 2018;115(20):5151-5156.
67. Paessler S, Veljkovic V. Prediction of influenza vaccine effectiveness for the influenza season 2017/18 in the US. *F1000Research*. 2017;6:2067.
68. Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. *Virol J*. 2018;15(1):17.
69. Nachbagauer R, Miller MS, Hai R, et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. *J Virol*. 2016;90(6):3268-3273.
70. Krammer F, Hai R, Yondola M, et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. *J Virol*. 2014;88(6):3432-3442.
71. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. *Nat Med*. 2015;21(9):1065-1070.
72. Liu WC, Nachbagauer R, Stadlbauer D, et al. Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical ferret model. *Front Immunol*. 2019;10:756.
73. Korenkov DA, Laurie KL, Reading PC, et al. Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model. *Infect Genet Evol*. 2018;64:95-104.
74. Rosendahl Huber SK, Camps MG, Jacobi RH, et al. Synthetic long peptide influenza vaccine containing conserved T and B cell epitopes reduces viral load in lungs of mice and ferrets. *PLoS ONE*. 2015;10(6):e0127969.
75. Price GE, Soboleski MR, Lo CY, et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. *Vaccine*. 2009;27(47):6512-6521.
76. Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. *PLoS ONE*. 2009;4(6):e6032.
77. Music N, Reber AJ, Kim MC, York IA, Kang SM. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. *Vaccine*. 2016;34(4):466-473.
78. Holzer B, Morgan SB, Matsuoka Y, et al. Comparison of heterosubtypic protection in ferrets and pigs induced by a single-cycle influenza vaccine. *J Immunol*. 2018;200(12):4068-4077.
79. Si L, Xu H, Zhou X, et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines. *Science*. 2016;354(6316):1170-1173.
80. Baz M, Boonnak K, Paskel M, et al. Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge. *MBio*. 2015;6(5):e01487-e1515.
81. Romanova J, Krenn BM, Wolschek M, et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. *PLoS ONE*. 2009;4(6):e5984.
82. Wang L, Liu SY, Chen HW, et al. Generation of a live attenuated influenza vaccine that elicits broad protection in mice and ferrets. *Cell Host Microbe*. 2017;21(3):334-343.
83. Cheng X, Zengel JR, Suguitan AL Jr, et al. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. *J Infect Dis*. 2013;208(4):594-602.

84. Min JY, Vogel L, Matsuoka Y, et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. *J Virol*. 2010;84(22):11950-11960.
85. Ann J, Samant M, Rheaume C, et al. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. *Vaccine*. 2014;32(43):5730-5739.
86. Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. *PLoS ONE*. 2014;9(2):e88979.
87. Bodewes R, Kreijtz JH, van Amerongen G, et al. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. *J Virol*. 2010;84(16):7943-7952.
88. Christensen D, Christensen JP, Korsholm KS, et al. Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant. *Front Immunol*. 2017;8:1928.
89. Yang J, Shim SM, Nguyen TQ, et al. Poly-gamma-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine. *Sci Rep*. 2017;7:44839.
90. Skibinski DA, Hanson BJ, Lin Y, et al. Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. *PLoS ONE*. 2013;8(10):e76571.
91. Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. *Nat Biotechnol*. 2012;30(12):1210-1216.
92. Pillet S, Kobasa D, Meunier I, et al. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. *Vaccine*. 2011;29(39):6793-6801.
93. Kreijtz JH, Wiersma LC, De Gruyter HL, et al. A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. *J Infect Dis*. 2015;211(5):791-800.
94. Bodewes R, Kreijtz JH, van Amerongen G, et al. Infection of the upper respiratory tract with seasonal influenza A(H3N2) virus induces protective immunity in ferrets against infection with A(H1N1)pdm09 virus after intranasal, but not intratracheal, inoculation. *J Virol*. 2013;87(8):4293-4301.
95. Bird NL, Olson MR, Hurt AC, et al. Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses. *PLoS ONE*. 2015;10(6):e0129768.
96. Cameron CM, Cameron MJ, Bermejo-Martin JF, et al. Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. *J Virol*. 2008;82(22):11308-11317.
97. Maines TR, Belser JA, Gustin KM, et al. Local innate immune responses and influenza virus transmission and virulence in ferrets. *J Infect Dis*. 2012;205(3):474-485.
98. Leon AJ, Banner D, Xu L, et al. Sequencing, annotation, and characterization of the influenza ferret infectome. *J Virol*. 2013;87(4):1957-1966.
99. Kobinger GP, Meunier I, Patel A, et al. Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. *J Infect Dis*. 2010;201(7):1000-1006.
100. Carolan LA, Butler J, Rockman S, et al. TaqMan real time RT-PCR assays for detecting ferret innate and adaptive immune responses. *J Virol Methods*. 2014;205:38-52.
101. Maier T, Guell M, Serrano L. Correlation of mRNA and protein in complex biological samples. *FEBS Lett*. 2009;583(24):3966-3973.
102. Martel CJ, Aasted B. Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. *Vet Immunol Immunopathol*. 2009;132(2-4):109-115.
103. Rutigliano JA, Doherty PC, Franks J, Morris MY, Reynolds C, Thomas PG. Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection. *J Immunol Methods*. 2008;336(1):71-77.
104. Reber AJ, Music N, Kim JH, Ganseboom S, Chen J, York I. Extensive T cell cross-reactivity between diverse seasonal influenza strains in the ferret model. *Sci Rep*. 2018;8(1):6112.
105. Hayashi S, Kikuchi Y, Harada K, Kawahara J-I. Cross-reactivity of monoclonal antibodies on peripheral blood cells from common marmosets by flow cytometry. *Cytometry Res*. 2007;17(1):21-28.
106. Rees J, Haig D, Mack V, Davis WC. Characterisation of monoclonal antibodies specific for hamster leukocyte differentiation molecules. *Vet Immunol Immunopathol*. 2017;183:40-44.
107. Layton DS, Xiao X, Bentley JD, et al. Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes. *J Immunol Methods*. 2017;444:29-35.
108. DiPiazza A, Richards K, Batarse F, et al. Flow cytometric and cytokine ELISpot approaches to characterize the cell-mediated immune response in ferrets following influenza virus infection. *J Virol*. 2016;90(17):7991-8004.
109. Albrecht RA, Liu W-C, Sant AJ, et al. Moving forward: recent developments for the ferret biomedical research model. *mBio*. 2018;9(4):e01113-18.
110. Music N, Reber AJ, Kim JH, York IA. Peripheral leukocyte migration in ferrets in response to infection with seasonal influenza virus. *PLoS ONE*. 2016;11(6):e0157903.
111. Music N, Reber AJ, Lipatov AS, et al. Influenza vaccination accelerates recovery of ferrets from lymphopenia. *PLoS ONE*. 2014;9(6):e100926.
112. Roberts KL, Shelton H, Stilwell P, Barclay WS. Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected in the ferret model. *PLoS ONE*. 2012;7(8):e43303.
113. van den Brand JM, Stittelaar KJ, van Amerongen G, et al. Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic avian influenza H5N1 virus infections in ferrets. *PLoS ONE*. 2012;7(8):e42343.
114. DiPiazza AT, Richards KA, Liu WC, Albrecht RA, Sant AJ. Analyses of cellular immune responses in ferrets following influenza virus infection. *Methods Mol Biol*. 2018;1836:513-530.
115. Richards KA, Chaves FA, Sant AJ. The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity. *Immunology*. 2011;133(2):246-256.
116. Angeletti D, Yewdell JW. Understanding and manipulating viral immunity: antibody immunodominance enters center stage. *Trends Immunol*. 2018;39(7):549-561.
117. Vidaña B, Majó N, Pérez M, Montoya M, Martorell J, Martínez J. Immune system cells in healthy ferrets. *Vet Pathol*. 2013;51(4):775-786.
118. Kirchenbaum GA, Allen JD, Layman TS, Sautto GA, Ross TM. Infection of ferrets with influenza virus elicits a light chain-biased antibody response against hemagglutinin. *J Immunol*. 2017;199(11):3798-3807.
119. Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen J-L. Host immune response to influenza A virus infection. *Front Immunol*. 2018;9:320.
120. O E, Lee Y-T, Ko E-J, et al. Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination. *J Virol*. 2014;88(14):7764-7775.
121. Frank GM, Angeletti D, Ince WL, et al. A simple flow-cytometric method measuring B cell surface immunoglobulin avidity enables characterization of affinity maturation to influenza A virus. *MBio*. 2015;6(4):e01156.
122. Angeletti D, Gibbs JS, Angel M, et al. Defining B cell immunodominance to viruses. *Nat Immunol*. 2017;18(4):456-463.

123. Altman MO, Angeletti D, Yewdell JW. Antibody immunodominance: the key to understanding influenza virus antigenic drift. *Viral Immunol.* 2018;31(2):142-149.
124. Nachbagauer R, Liu WC, Choi A, et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. *NPJ Vaccines.* 2017;2:26.
125. The JS. Potential role of Fc-receptor functions in the development of a universal influenza vaccine. *Vaccines (Basel).* 2018;6(2):27.
126. Schultz-Cherry S. Viral interference: the case of influenza viruses. *J Infect Dis.* 2015;212(11):1690-1691.
127. Laurie KL, Horman W, Carolan LA, et al. Evidence for viral interference and cross-reactive protective immunity between influenza B virus lineages. *J Infect Dis.* 2018;217(4):548-559.
128. van Asten L, Bijkerk P, Fanoy E, et al. Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections. *Influenza Other Respir Viruses.* 2016;10:14-26.
129. Lai C, Wang K, Zhao Z, et al. C-C motif chemokine ligand 2 (CCL2) mediates acute lung injury induced by lethal influenza H7N9 virus. *Front Microbiol.* 2017;8:587.
130. Schultz-Cherry S. Role of NK cells in influenza infection. *Influenza Pathogenesis Control.* 2014;11:109-120.
131. Waithman J, Mintern JD. Dendritic cells and influenza A virus infection. *Virulence.* 2012;3(7):603-608.
132. Fouchier R, Tate MD, Ioannidis LJ, et al. The role of neutrophils during mild and severe influenza virus infections of mice. *PLoS ONE.* 2011;6(3):e17618.
133. Cline TD, Beck D, Bianchini E. Influenza virus replication in macrophages: balancing protection and pathogenesis. *J Gen Virol.* 2017;98(10):2401-2412.
134. Auladell M, Jia X, Hensen L, et al. Recalling the future: immunological memory toward unpredictable influenza viruses. *Front Immunol.* 2019;10:1400.
135. Manocha S, Walley KR, Russell JA. Severe acute respiratory distress syndrome (SARS): a critical care perspective. *Crit Care Med.* 2003;31(11):2684-2692.
136. Martina BE, Haagmans BL, Kuiken T, et al. Virology: SARS virus infection of cats and ferrets. *Nature.* 2003;425(6961):915.
137. Roberts A, Lamirande EW, Vogel L, et al. Animal models and vaccines for SARS-CoV infection. *Virus Res.* 2008;133(1):20-32.
138. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. *J Virol.* 2004;78(22):12672-12676.
139. Kobinger GP, Figueredo JM, Rowe T, et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. *Vaccine.* 2007;25(28):5220-5231.
140. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. *J Virol.* 2008;82(5):2040-2055.
141. de La Vega M-A, Soule G, Tran KN, et al. Modeling Ebola virus transmission using ferrets. *mSphere.* 2018;3(5).
142. Cross RW, Speranza E, Borisevich V, et al. Comparative transcriptomics in Ebola Makona-infected ferrets, nonhuman primates, and humans. *J Infect Dis.* 2018;218(suppl\_5):S486-S495.
143. Peng X, Alfoldi J, Gori K, et al. The draft genome sequence of the ferret (*Mustela putorius furo*) facilitates study of human respiratory disease. *Nat Biotechnol.* 2014;32(12):1250-1255.
144. Montague MJ, Li G, Gandolfi B, et al. Comparative analysis of the domestic cat genome reveals genetic signatures underlying feline biology and domestication. *Proc Natl Acad Sci USA.* 2014;111(48):17230-17235.
145. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature.* 2005;438(7069):803-819.
146. Lefranc MP, Giudicelli V, Duroux P, et al. IMGT(R), the international ImMunoGeneTics information system(R) 25 years on. *Nucleic Acids Res.* 2015;43(Database issue):D413-D422.
147. Cui A, Di Niro R, Vander Heiden JA, et al. A model of somatic hypermutation targeting in mice based on high-throughput Ig sequencing data. *J Immunol.* 2016;197(9):3566-3574.
148. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. *J Immunol Methods.* 2008;329(1-2):112-124.
149. Allen RL, Walseng E, Wälchli S, et al. Soluble T-cell receptors produced in human cells for targeted delivery. *PLoS ONE.* 2015;10(4):e0119559.
150. Jersmann HP. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. *Immunol Cell Biol.* 2005;83(5):462-467.
151. Liyanage SE, Gardner PJ, Ribeiro J, et al. Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models. *Exp Eye Res.* 2016;151:160-170.
152. Sánchez-Torres C, García-Romo GS, Cornejo-Cortés MA, Rivas-Carvalho A, Sánchez-Schmitz G. CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. *Int Immunol.* 2001;13(12):1571-1581.
153. Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, Dransfield I. CD66: role in the regulation of neutrophil effector function. *Eur J Immunol.* 1996;26(12):2924-2932.
154. Bergeron LM, McCandless EE, Dunham S, et al. Comparative functional characterization of canine IgG subclasses. *Vet Immunol Immunopathol.* 2014;157(1-2):31-41.
155. Tabel H, Ingram DG. Immunoglobulins of mink. Evidence for five immunoglobulin classes of 7S type. *Immunology.* 1972;22(6):933-942.
156. Strietzel CJ, Bergeron LM, Oliphant T, Mutchler VT, Choromanski LJ, Bainbridge G. In Vitro functional characterization of feline IgGs. *Vet Immunol Immunopathol.* 2014;158(3-4):214-223.
157. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. *J Virol.* 2013;87(10):5512-5522.
158. Ana-Sosa-Batiz F, Vandervan H, Jegaskanda S, et al. Influenza-specific antibody-dependent phagocytosis. *PLoS ONE.* 2016;11(4):e0154461.
159. Vandervan HA, Ana-Sosa-Batiz F, Jegaskanda S, et al. What lies beneath: antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. *EBioMedicine.* 2016;8:277-290.
160. de Vries RD, Nieuwkoop NJ, Pronk M, et al. Influenza virus-specific antibody dependent cellular cytotoxicity induced by vaccination or natural infection. *Vaccine.* 2017;35(2):238-247.
161. Vandervan HA, Liu L, Ana-Sosa-Batiz F, et al. Fc functional antibodies in humans with severe H7N9 and seasonal influenza. *JCI Insight.* 2017;2(13):pii: 92750
162. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. *J Immunol.* 2014;193(2):469-475.
163. Vidana B, Majo N, Perez M, Montoya M, Martorell J, Martinez J. Immune system cells in healthy ferrets: an immunohistochemical study. *Vet Pathol.* 2014;51(4):775-786.
164. Ochi A, Danesh A, Seneviratne C, et al. Cloning, expression and immunoassay detection of ferret IFN-gamma. *Dev Comp Immunol.* 2008;32(8):890-897.
165. Fonville JM, Fraaij PL, de Mutsert G, et al. Antigenic maps of influenza A(H3N2) produced with human antisera obtained after primary infection. *J Infect Dis.* 2016;213(1):31-38.
166. Liu S, Behzadi MA, Sun W, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. *J Clin Invest.* 2018;128(11):4992-4996.

167. Skowronski DM, Hottes TS, Janjua NZ, et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. *Can Med Assoc J*. 2010;182(17):1851-1856.
168. Zaccour M, Ward BJ, Brewer A, et al. Standardization of hemagglutination inhibition assay for influenza serology allows for high reproducibility between laboratories. *Clin Vaccine Immunol*. 2016;23(3):236-242.
169. Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. *Nature*. 1981;290(5808):713-717.
170. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). *Cell*. 1982;31(2):417-427.
171. Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Isolation and characterization of human monoclonal antibodies that recognize the influenza A(H1N1)pdm09 virus hemagglutinin receptor-binding site and rarely yield escape mutant viruses. *Front Microbiol*. 2018;9:2660.
172. Sun W, Kang DS, Zheng A, et al. Antibody responses toward the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets, and humans. *J Virol*. 2019;93(2).pii: e01673-18.
173. Xie H, Wan X-F, Ye Z, et al. H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. *Sci Rep*. 2015;5:15279.
174. Lee MS, Yang CF. Cross-reactive H1N1 antibody responses to a live attenuated influenza vaccine in children: implication for selection of vaccine strains. *J Infect Dis*. 2003;188(9):1362-1366.
175. Aasted B. Mink infected with Aleutian disease virus have an elevated level of CD8-positive T-lymphocytes. *Vet Immunol Immunopathol*. 1989;20(4):375-385.

**How to cite this article:** Wong J, Layton D, Wheatley AK, Kent SJ. Improving immunological insights into the ferret model of human viral infectious disease. *Influenza Other Respi Viruses*. 2019;00:1–12. <https://doi.org/10.1111/irv.12687>